Cell Therapy Next Current Issue

The following articles appeared in the print edition of Cell Therapy Next.

Table of Contents

• Despite challenges, CAR-T may have ‘expanded role’ for children Drew Amorosi
• Gene-edited stem cells show curative potential for beta-thalassemia, sickle cell disease Drew Amorosi
• SITC creates endowed scholars fund, announces inaugural recipient
• FDA clears IND application for stem cell therapy to treat type 1 diabetes
• FDA lifts clinical hold on trial of CAR-T for metastatic pancreatic, prostate cancers
• FDA lifts hold on clinical trial for allogeneic CAR-T for advanced myeloma
• Manufacturers submit rolling BLA to FDA for CAR-T to treat advanced multiple myeloma
• Approval of new CAR-T may have ‘immediate impact’ on treatment of large B-cell lymphoma Drew Amorosi
• Better understanding of late effects needed to guide survivorship care after CAR-T Drew Amorosi
• Molecular, cellular characteristics of CAR T-cell therapy may predict response, toxicity Drew Amorosi
• CAR-T a ‘fantastic improvement’ over available therapies for advanced multiple myeloma Drew Amorosi
• CAR-T confers durable clinical benefit in high-risk indolent non-Hodgkin lymphoma Drew Amorosi
• CAR-T effective as first-line therapy for high-risk large B-cell lymphoma Drew Amorosi
• Clinicians need more education on emerging cancer immunotherapies, survey shows Drew Amorosi
• Letetresgene autoleucel safe, active in advanced synovial sarcoma Drew Amorosi
• Radiation therapy safe before CAR T-cell infusion for advanced multiple myeloma Drew Amorosi
• Tumor-infiltrating lymphocytes plus pembrolizumab active in metastatic HNSCC Drew Amorosi
• Cell therapy reduces cardiac death, has no effect on nonfatal heart failure events